Want to see OTLK full AI Analyst Report?
OTLK Stock Chart & Stats
$0.31
-$0.17(-7.61%)
At close: 4:00 PM EST
$0.31
-$0.17(-7.61%)
Day’s Range― - ―
52-Week Range$0.16 - $3.39
Previous CloseN/A
Volume358.39K
Average Volume (3M)13.75M
Market Cap
$250.58M
Enterprise Value$36.28
Total Cash (Recent Filing)$7.75M
Total Debt (Recent Filing)$27.19M
Price to Earnings (P/E)―
Beta1.42
Next Earnings
Aug 13, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.36
Shares Outstanding186,997,000
10 Day Avg. Volume9,265,133
30 Day Avg. Volume13,754,715
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)-1.15
Price to Sales (P/S)26.09
P/FCF Ratio-0.71
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.81Price Target Upside1772.58% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.48
Revenue Forecast (FY)$14.26M
Bulls Say, Bears Say
Bulls Say
FDA Acceptance And PDUFA DateThe FDA's Class 1 acceptance and defined PDUFA date concentrates the remaining regulatory work on labeling, materially shortening approval uncertainty. If approved, the product transitions the company from development-stage to potential commercial-stage, altering long-term revenue prospects and strategic options.
Successful FDA Appeal Validating EfficacyWinning the Formal Dispute Resolution and having the Office of New Drugs confirm sufficient evidence reduces the risk of additional trials and strengthens the approval pathway. This regulatory validation is a durable de-risking event that improves the probability of eventual commercialization.
Demonstrated Capital-market AccessAn effective shelf registration plus ATM and completed registered direct financings show the company can tap public markets for financing. That persistent access supports near-term funding for pre-launch, regulatory and commercialization activities, sustaining operations while approval is pursued.
Bears Say
Negative Shareholder EquityDeep and persistent negative equity reflects accumulated losses that weaken the capital base and limit financial flexibility. Over months this constrains strategic options, raises counterparty concerns, and increases reliance on external financing to sustain operations and commercialization plans.
Consistent Cash BurnSustained negative operating and free cash flow indicate the business cannot self-fund R&D or launch activities. Absent timely approval and commercial revenue, ongoing cash burn makes the company dependent on external capital, creating durable execution risk over the next several months.
Ongoing Dilutive Financings And Warrant RepricingFrequent registered direct offerings, ATM capacity, lowered warrant exercise prices and a shareholder-approved increase in authorized shares structurally enable further dilution. Over time this reduces existing shareholder ownership and can complicate future capital raises and investor returns.
Outlook Therapeutics News
OTLK FAQ
What was Outlook Therapeutics’s price range in the past 12 months?
Outlook Therapeutics lowest stock price was $0.16 and its highest was $3.39 in the past 12 months.
What is Outlook Therapeutics’s market cap?
Outlook Therapeutics’s market cap is $250.58M.
When is Outlook Therapeutics’s upcoming earnings report date?
Outlook Therapeutics’s upcoming earnings report date is Aug 13, 2026 which is in 20 days.
How were Outlook Therapeutics’s earnings last quarter?
Outlook Therapeutics released its earnings results on May 15, 2026. The company reported -$0.16 earnings per share for the quarter, missing the consensus estimate of -$0.121 by -$0.039.
Is Outlook Therapeutics overvalued?
According to Wall Street analysts Outlook Therapeutics’s price is currently Undervalued.
Does Outlook Therapeutics pay dividends?
Outlook Therapeutics does not currently pay dividends.
What is Outlook Therapeutics’s EPS estimate?
Outlook Therapeutics’s EPS estimate is -0.11.
How many shares outstanding does Outlook Therapeutics have?
Outlook Therapeutics has 186,997,000 shares outstanding.
What happened to Outlook Therapeutics’s price movement after its last earnings report?
Outlook Therapeutics reported an EPS of -$0.16 in its last earnings report, missing expectations of -$0.121. Following the earnings report the stock price went up 0.439%.
Which hedge fund is a major shareholder of Outlook Therapeutics?
Currently, no hedge funds are holding shares in OTLK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Outlook Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.81 (1772.58% Upside)
$5.81 (1772.58% Upside)
Blogger Sentiment
Bullish
OTLK Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 151.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $5.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.2%
Last 30 Days ▼ 3.6%
Last 30 Days ▼ 3.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-35.57%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
14.77%
Trailing 12-Months
Company Description
Outlook Therapeutics
Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010, is an ophthalmic formulation of bevacizumab currently undergoing crucial Phase III clinical trials. This investigational product is being evaluated for its potential to treat wet age-related macular degeneration and other serious retinal diseases. The company has forged strategic collaboration and licensing agreements with several partners, including IPCA Laboratories Limited, Laboratorios Liomont, S.A. de C.V., BioLexis Pte. Ltd., and Zhejiang Huahai Pharmaceutical Co., Ltd. Incorporated in 2010, the firm was formerly known as Oncobiologics, Inc., changing its name to Outlook Therapeutics, Inc. in November 2018. Its corporate base is located in Iselin, New Jersey.
OTLK Stock 12 Month Forecast
Average Price Target
$5.81
▲(1772.58% Upside)
Technical Analysis
Ownership Overview
14.18% Insiders
1.41% Mutual Funds
0.13% Other Institutional Investors
81.59% Public Companies and
Individual Investors